Neha Kakkar and Rohanpreet Singh, on Tuesday, filled their respective Instagram diaries with pictures from their Dubai honeymoon and we are in love with them.
Neha Kakkar and Rohanpreet Singh, on Tuesday, filled their respective Instagram diaries with pictures from their Dubai honeymoon and we are in love with them.
The Human Machine Interface Market will grow by $ 3.15 bn during 2020-2024
The Dow’s journey to 30,000 has been nothing short of remarkable. It’s the latest milestone in a post-election rally that’s been fueled by promising results from three potential COVID-19 vaccines. "The idea that we're hitting Dow 30,000 in a pandemic year, the same year where it almost hit 18,000, is utterly outrageous.” Oanda analyst Craig Erlam told the Wall Street Journal The blue-chip index flirted with 30,000 in February, then the pandemic hit. In March, with much of the U-S in lockdown because of the virus, the Dow fell below 19,000. Since then, the index has soared more than 60%, setting multiple records along the way. The Dow is now on track to close out its best month since 1987.
Rio Tinto's destruction of sacred Indigenous rock shelters in Australia this year has dismayed and galvanised a swathe of investors who want big changes in how mining firms manage heritage issues and have begun to tell them so. They have stepped up communication with mining companies both in volume and frequency, putting them on notice to improve accountability and risk management, according to Reuters interviews with two dozen major investors and corporate governance advisers. Regnan is part of the Pendal Group which has some A$94.8 billion(52.22 billion pounds)under management.
A period of uncertainty at cricket's world governing body ended Tuesday with Greg Barclay being elected ICC chairman after a second round of voting. New Zealand Cricket chairman Barclay, an Auckland-based commercial lawyer, was elected to the independent post ahead of Imran Khwaja. Khwaja had served as interim chairman of the International Cricket Council following the resignation of India’s Shashank Manohar in July.
Triton Digital Releases the October 2020 Latin America Podcast Report
Brentford extended their unbeaten run to six Championship games as in-from striker Ivan Toney scored the only goal of the game in a 1-0 victory at Barnsley. Toney was largely kept quiet throughout the 90 minutes but his effort midway through the second half - his 11th in as many league outings - proved decisive. The victory was Brentford's first in four outings and moved them within two points of the play-off places.
‘Christmas cannot be normal,’ says prime minister
MORRISVILLE, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced the completion of the previously announced offering of $600.0 million aggregate principal amount of 3.625% senior notes due 2029 (the “Notes”). The Notes are guaranteed, jointly and severally, on a senior unsecured basis, by certain of the Company’s subsidiaries. The net proceeds of the offering will be used for general corporate purposes, including the funding of acquisitions, and for repayment of indebtedness.The Notes were offered only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States, only to non-U.S. investors pursuant to Regulation S. The Notes will not be and have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.The Company also announced that it entered into an amendment to the credit agreement governing its existing senior secured credit facilities pursuant to which, among other things, the Issuer has extended the maturity date thereof to August 2024.This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers of the Notes were made only by means of a private offering memorandum.Forward-Looking StatementsExcept for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include, but are not limited to: reliance on key personnel; principal investigators and patients; general and international economic, political, and other risks, including currency and stock market fluctuations and the uncertain economic environment; any inability to satisfy or any failure to waive the closing conditions related to the Company’s acquisition of SHCR Holdings Corporation (“Synteract”); any failure to realize the anticipated benefits of the acquisition of Synteract; risks related to the COVID-19 pandemic; the Company's ability to adequately price its contracts and not overrun cost estimates; any adverse effects from the Company's customer or therapeutic area concentration; the Company's ability to maintain or generate new business awards; the Company's ability to increase its market share, grow its business, and execute its growth strategies; the Company's backlog not being indicative of future revenues and its ability to realize the anticipated future revenue reflected in its backlog; fluctuations in the Company's operating results and effective income tax rate; risks related to the Company's information systems and cybersecurity; changes and costs of compliance with regulations related to data privacy; risks related to the United Kingdom’s withdrawal from the European Union; risks related to the Company's transfer pricing policies; failure to perform services in accordance with contractual requirements, regulatory requirements and ethical considerations; risks relating to litigation and government investigations; risks associated with the Company's early phase clinical facilities; insurance risk; risks of liability resulting from harm to patients; success of investments in the Company's customers’ business or drugs; foreign currency exchange rate fluctuations; risks associated with acquired businesses, including the ability to integrate acquired operations, products, and technologies in the Company’s business; risks related to the Company's income tax expense and tax reform; risks relating to the Company's intellectual property; risks associated with the Company's acquisition strategy; failure to realize the full value of goodwill and intangible assets; restructuring risk; potential violations of anti-corruption and anti-bribery laws; risks related to the Company's dependence on third parties; downgrades of the Company's credit ratings; competition in the biopharmaceutical services industry; changes in outsourcing trends; regulatory risks; trends in the Company's customers’ businesses; the Company's ability to keep pace with rapid technological change; risks related to the Company's indebtedness; fluctuations in the Company's financial results and stock price; and other risk factors set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 as updated by the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, and other SEC filings, copies of which are available free of charge on the SEC website at www.sec.gov. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.About Syneos HealthSyneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Investor Relations Contact: Ronnie Speight Senior Vice President, Investor Relations Phone: +1 919 745 2745 Email: Investor.Relations@syneoshealth.comPress/Media Contact: Danielle DeForge Vice President, External Communications Phone: +1 202 210 5992 Email: firstname.lastname@example.org
Clovis Oncology Announces Exercise by Existing Holder of Option to Purchase an Additional $7.5 Million Aggregate Principal Amount of the Company’s 4.5
RelSup - Supplements that You Can Trust - Expanding Retail Distribution Throughout U.S. RelSup dietary supplements available at Amazon include: 1) Supracol, which targets the colon to support digestive function, contains butyric acid, prebiotics, and probiotics. The Supracol capsule is gastro-resistant, which prevents it from prematurely breaking down and targets the lower intestine. 2) Artizak, which provides strong support for liver, gall bladder, and digestive function, helps promote metabolic health. Artizak contains a unique set of ingredients that include artichoke leaf extract, dandelion root extract, inositol, and choline dihydrogen. Artizak comes in a 10ml liquid foil pack. 3) Lactacol, which contains an enzyme, lactase, which aids in the digestion of dairy products. 4) Hepazak, which was developed to support liver health by providing unique ingredients that promote liver injury protection, contains a potent antioxidant, reduces acidosis, and aids in eliminating dyspeptic disorders. PALM BEACH, FL, Nov. 24, 2020 (GLOBE NEWSWIRE) -- For the fourth year in a row, more than 70 percent of Americans reported taking dietary supplements.The Council for Responsible Nutrition’s annual survey also reported that 43 percent of supplement users changed their routine since the start of the pandemic. Ninety-one percent of these dietary supplement users have increased their intake because of COVID-19.“The CRN survey shows what we know at RelSup. Consumers are taking dietary supplements at record numbers,” said Steven Berens, president of RelSup, the U.S. distributor. “American consumers want quality dietary supplements that they can trust, which is why we developed our flagship products.RelSup dietary supplements available at Amazon include: * Supracol, which targets the colon to support digestive function, contains butyric acid, prebiotics, and probiotics. The Supracol capsule is gastro-resistant, which prevents it from prematurely breaking down and targets the lower intestine. * Artizak, which provides strong support for liver, gall bladder, and digestive function, helps promote metabolic health. Artizak contains a unique set of ingredients that include artichoke leaf extract, dandelion root extract, inositol, and choline dihydrogen. Artizak comes in a 10ml liquid foil pack. * Lactacol, which contains an enzyme, lactase, which aids in the digestion of dairy products. * Hepazak, which was developed to support liver health by providing unique ingredients that promote liver injury protection, contains a potent antioxidant, reduces acidosis, and aids in eliminating dyspeptic disorders. Hepazak comes in a 10ml liquid foil pack.“The pandemic has affected all of us,” Berens said. “COVID-19 has made all of us more conscious about our health. Many people take dietary supplements regularly to get healthy and stay healthy.”Berens said more consumers are looking to dietary supplements to help them with daily health issues.“RelSup developed its dietary supplements to help people with common digestive problems,” Berens said, adding that RelSup also offers supplements for liver health and to aid digestion of dairy products.“Our research and development team created quality supplements that you can trust. Supracol, Artizak, Lactacol, and Hepazak are nutritional supplements that you should try,” Berens added.To purchase RelSup supplements, visit Amazon.Attachment * RelSup_4Products CONTACT: Robert Grant RelSup 561-421-3045 email@example.com
England soccer player Jack Grealish pleaded guilty to two driving offenses on Tuesday, the first coming in March during lockdown in Britain when a witness said he found the Aston Villa captain slurring his words after crashing his car.
'Disastrous' or a smart move? How Victoria's case for an electric car usage tax stacks upAs Australia lags in the global take-up of electric vehicles, there are concerns the proposed tax would raise prices and put off potential buyers
Wichita State landed in Sioux Falls, South Dakota on Monday afternoon, masked up and looking forward to tipping off the season in the Crossover Classic.
TORONTO, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Revival Gold Inc. (TSXV: RVG, OTCQB: RVLGF) (“Revival Gold” or the "Company"), a growth-focused gold exploration and development company, announces voting results for the election of directors at its Annual General Meeting (“AGM”) of Shareholders held on November 24th, 2020, in Toronto. A total of 33,508,817 common shares representing 47.1% of the Company’s issued and outstanding shares were voted in connection with the AGM. Shareholders approved all items of business before the AGM including the election of Directors as follows:Director NomineesVotes For% of Votes Cast Wayne Hubert27,043,04899.8% Hugh Agro27,063,30499.9% Donald Birak27,043,04899.8% Robert Chausse27,049,21999.9% Maura Lendon27,033,21999.8% Michael Mansfield27,047,21999.9% Carmelo Marrelli24,509,46990.5% Following the AGM, Revival Gold re-appointed Wayne Hubert as Chairman of the Board, Robert Chausse as Audit Committee Chair, Carmelo Marrelli as Compensation Committee Chair and Donald Birak as Technical, Safety, Environment and Social Responsibility Committee Chair, and appointed Maura Lendon as Corporate Governance and Nominating Committee Chair.Subject to regulatory approval, Revival Gold has granted 1,325,000 incentive stock options to directors, officers, and consultants of the Company as part of its annual compensation plan. Pursuant to the Company’s Stock Option Plan, the options are exercisable at a price of $1.00 per share for a period of five years and are subject to vesting provisions.About Revival Gold Inc.Revival Gold Inc. is a growth-focused gold exploration and development company. The Company has the right to acquire a 100% interest in Meridian Beartrack Co., owner of the former producing Beartrack Gold Project located in Idaho, USA. Revival Gold also owns rights to a 100% interest in the neighboring Arnett Gold Project.Beartrack-Arnett is the largest past-producing gold mine in Idaho. A Preliminary Economic Assessment has been completed for a first phase restart of heap leach operations to produce 72,000 ounces of gold per year over an initial seven-year mine life at an AISC of $1,057 per ounce of gold. Meanwhile, exploration continues focused on expanding the current Indicated Mineral Resource of 36.6 million tonnes at 1.15 g/t gold containing 1.36 million ounces of gold and Inferred Mineral Resource of 47.1 million tonnes at 1.08 g/t gold containing 1.64 million ounces of gold. The mineralized trend at Beartrack extends for over 5 km and is open on strike and at depth. Mineralization at Arnett is open in all directions.For further details, including key assumptions, parameters and methods used to estimate the Mineral Resources, and data verification, please see the Company’s press release dated November 17th, 2020 and NI 43-101 compliant technical report titled “Technical Report on the Beartrack-Arnett Gold Project, Lemhi County, Idaho, USA” dated February 21st, 2020.Revival Gold has approximately 71.2 million shares outstanding and had a cash balance of approximately C$12.7 million on September 30th, 2020. Additional disclosure including the Company’s financial statements, technical reports, news releases and other information can be obtained at www.revival-gold.com or on SEDAR at www.sedar.com.For further information, please contact:Hugh Agro, President & CEO or Adam Rochacewich, CFO Telephone: (416) 366-4100 or Email: firstname.lastname@example.org Cautionary StatementNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. Technical information in this news release has been reviewed and approved by Steven T. Priesmeyer, C.P.G., Vice President Exploration, Revival Gold Inc. and Rodney A. Cooper, P.Eng., a consultant to Revival Gold Inc., Qualified Persons within the meaning of National Instrument 43-101 – Standards of Disclosure for Mineral Projects.This News Release includes certain “forward-looking statements” which are not comprised of historical facts. Forward-looking statements include estimates and statements that describe the Company’s future plans, objectives or goals, including words to the effect that the Company, or management, expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to the Company, the Company provides no assurance that actual results will meet management’s expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward-looking information in this news release includes, but is not limited to, the Company’s intentions regarding its objectives, goals or future plans and statements. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, the Company’s ability to predict or counteract the potential impact of COVID-19 coronavirus on factors relevant to the Company’s business, failure to identify additional mineral resources, failure to convert estimated mineral resources to reserves with more advanced studies, the inability to eventually complete a feasibility study which could support a production decision, the preliminary nature of metallurgical test results may not be representative of the deposit as a whole, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, political risks, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects, capital, operating and reclamation costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry, and those risks set out in the Company’s public documents filed on SEDAR. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
nVent Electric plc (NYSE:NVT) ("nVent"), a global leader in electrical connection and protection solutions has introduced a redesigned SCHROFF website. The new SCHROFF.nVent.com features solutions for several industries including aerospace and defense, data center and networking, rail and transportation, telecommunications and test and measurement. It offers a best-in-class digital customer experience to enable design engineers to find, design and buy products more efficiently.
NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of investors that purchased Precigen, Inc. f/k/a Intrexon Corporation (NASDAQ: PGEN; XON) securities between May 10, 2017 and September 25, 2020 (the “Class Period”). Investors have until December 4, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action.On September 25, 2020, the U.S. Securities and Exchange Commission (“SEC”) issued a cease and desist order against Precigen. The cease and desist order involved “inaccurate reports concerning the company’s purported success converting relatively inexpensive natural gas into more expensive industrial chemicals using a proprietary methane bioconversion (‘MBC’) program.” The order noted that the Company was “primarily using significantly more expensive pure methane for the relevant laboratory experiments but was indicating that the results had been achieved using natural gas.” The cease-and-desist order further stated that although the Company “pitched the MBC program privately to numerous potential business partners over the course of 2017 and 2018” and “[a] number of these potential partners performed due diligence on the MBC program including reviewing lab results and plans for commercialization. [The Company] has not yet found a partner for the MBC program.”The complaint, filed on October 5, 2020, alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose to investors that: (1) the Company was using pure methane as feedstock for its announced yields for its methanotroph bioconversion platform instead of natural gas; (2) yields from natural gas as a feedstock were substantially lower than the aforementioned pure methane yields; (3) due to the substantial price difference between pure methane and natural gas, pure methane was not a commercially viable feedstock; (4) the Company’s financial statements for the quarter ended March 31, 2018 were false and could not be relied upon; (5) the Company had material weaknesses in its internal controls over financial reporting; (6) the Company was under investigation by the SEC since October 2018; and (7) as a result of the foregoing, defendants’ public statements were materially false and misleading at all relevant times.If you purchased Precigen securities during the Class Period and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at email@example.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.Contact Information: Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Melissa Fortunato, Esq. Marion Passmore, Esq. (212) 355-4648 firstname.lastname@example.org www.bespc.com
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Interface, Inc. (NASDAQ: TILE) between March 2, 2018 and September 28, 2020, inclusive (the "Class Period") of the important January 11, 2021 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for Interface investors under the federal securities laws.
WINNIPEG, Manitoba, Nov. 24, 2020 (GLOBE NEWSWIRE) -- DELTA 9 CANNABIS INC. (TSX: DN) (OTCQX: VRNDF) ("Delta 9" or the "Company"), is pleased to announce it has expanded its click-and-collect and same-day home delivery service program to the Thompson and Brandon, Manitoba markets. As a result, Delta 9 becomes the only retail store chain offering the above services in Winnipeg, Brandon, and Thompson, Manitoba. “As Canada deals with the second wave of COVID-19, contactless shopping options and access to cannabis products while enabling social distancing become an essential part of our business offering,” said John Arbuthnot, CEO of Delta 9. “As we have rolled out increased online services, we have noticed a major increase in the usage of our click-and-collect and same-day delivery programs with online sales up 265% over last year and with customer basket sizes much larger than in-store. If these consumer trends continue in a post-COVID world Delta 9 will be prepared as a market leader with innovative online services.”The Company is pleased to provide the next phase of convenience for customers and further enhance safety during the COVID-19 pandemic by minimizing contact time between customers and staff. With the click of a mouse, customers can browse and sort through a complete inventory of cannabis products by store and reserve any products from whichever retail location that is most convenient.Delta 9’s online platform features allow an order to be ready in two hours or less along with delivery services for all Manitobans. Customers will receive direct email and text order updates from their chosen store and can visit the Delta 9 website to seamlessly place an order. Customer service operators are available by phone or online chat.“We custom architected and developed a made in Manitoba solution to meet the current demands of our customers. Building upon what Shopify provides out of the box today, we were able to create a seamless omnichannel experience for both online and in-store shopping.” said Matthew Sodomsky, CTO of Delta 9.Check our Click-and-Collect and Same Day Delivery on the Delta 9 website today. https://www.delta9.ca/ For more information contact:Investor & Media Contact: Ian Chadsey VP Corporate Affairs Mobile: 204-898-7722 E-mail: email@example.com About Delta 9 Cannabis Inc.Delta 9 Cannabis Inc. is a vertically integrated cannabis company focused on bringing the highest quality cannabis products to market. Delta 9's wholly-owned subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of medical and recreational cannabis and operates an 80,000 square foot production facility in Winnipeg, Manitoba, Canada. Delta 9 owns and operates a chain of retail stores under the Delta 9 Cannabis Store brand. Delta 9's shares trade on the Toronto Stock Exchange under the symbol "DN" and on the OTCQX under the symbol "VRNDF". For more information, please visit www.delta9.ca. Disclaimer for Forward-Looking InformationCertain statements in this release may be forward-looking statements, which reflect the expectations of management regarding the Company’s Click and Collect and Home delivery service plans and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include Click and Collect and Home delivery service plans. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including all risk factors set forth in the annual information form of Delta 9 dated March 19, 2020 which has been filed on SEDAR. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.
NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of JPMorgan Chase & Co. (NYSE: JPM), First American Financial Corporation (NYSE: FAF), Bayerische Motoren Werke AG (“BMW”) (Other OTC: BMWYY, BAMXF), and Zosano Pharma Corporation (NASDAQ: ZSAN). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. JPMorgan Chase & Co. (NYSE: JPM) Class Period: February 23, 2016 to September 23, 2020Lead Plaintiff Deadline: December 23, 2020On November 6, 2018, the Department of Justice announced in a press release that former JPMorgan precious metals trader John Edmonds pled guilty to commodities fraud and a spoofing conspiracy.On August 20, 2019, the Department of Justice announced that another JPMorgan employee, Christian Trunz, pled guilty to spoofing charges, and had done so with the knowledge and consent of his supervisors.On September 23, 2020, Bloomberg reported that the Company was nearing a settlement to resolve the spoofing charges.On this news, shares of JPMorgan stock fell $2.04 per share, or 2%, to close at $92.74 per share on September 23, 2020.On September 29, 2020, the Commodity Futures Trading Commission (“CFTC”) formally announced that it had ordered JPMorgan to pay $920 million to settle the spoofing and manipulation charges. According to the order, the Company failed to monitor its employees and ignored multiple red flags. The Company also provided the CFTC with misleading information.The complaint, filed on October 24, 2020, alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) traders at the Company, with the knowledge and consent of their superiors, manipulated the precious metals market by “spoofing,” or placing fake orders to generate the appearance of market demand; (2) the Company had insufficient controls and compliance protocols to enable it to identify and stop the misconduct; (3) the Company’s earnings in the physical commodity market were, at least in part, ill-gotten; (4) such conduct would result in enhanced regulatory scrutiny; (5) the Company provided misleading information to CFTC investigators at early stages of the investigation into the misconduct; (6) resolution of the governmental investigation into the Company would result in a record-breaking $920 million fine; and (7) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.For more information on the JPMorgan securities class action case go to: https://bespc.com/cases/JPMFirst American Financial Corporation (NYSE: FAF) Class Period: February 17, 2017 to October 22, 2020Lead Plaintiff Deadline: December 24, 2020On May 24, 2019, KrebsOnSecurity.com (“KrebsOnSecurity”), a noted cybersecurity blog, reported a massive data exposure by First American in which approximately 885 million customer files were exposed by First American.On this news, shares of First American fell $3.46, or over 6%, to close at $51.80 per share on May 25, 2019.On October 22, 2020, First American filed a quarterly report on Form 10-Q with the SEC, announcing that the Company had received a Wells Notice regarding its massive security breach.On this news the price of First American shares fell approximately $4.83 per share, or 9%, to close at $46.75 per share on October 22, 2020.The complaint, filed on October 25, 2020, alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company failed to implement basic security standards to protect its customers’ sensitive personal information and data; (2) the Company faced a heightened risk of cybersecurity failure due to its automation and efficiency initiatives; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times.For more information on the First American Financial class action go to: https://bespc.com/cases/FAFBayerische Motoren Werke AG (“BMW”) (Other OTC: BMWYY, BAMXF)Class Period: November 3, 2015 to September 24, 2020Lead Plaintiff Deadline: December 28, 2020On December 23, 2019, the Wall Street Journal reported that the SEC was probing BMW’s sales practices.On this news, BMWYY ADRs fell $1.33 per ADR, or nearly 6.87%, to close at $18.02 per ADR on December 23, 2019. The same day, BAMXF ADRs fell $1.25, or 1.5%, to close at $80.60.On September 24, 2020, the SEC announced a settlement agreement with BMW regarding the investigation. According to the SEC’s order, from January 2015 to March 2017, BMW US “used its demonstrator and service loaner programs to boost reported retail sales volume and meet internal targets, resulting in demonstrator and loaner vehicles accounting for over one quarter of BMW [US]’s reported retail sales in this period.” Additionally, the order found that BMW US, from 2015 to 2019, maintained a reserve of unreported retail vehicles sales – referred to internally as the “bank” – that it used to meet internal monthly sales targets regardless of when the actual sale occurred. The order also found that BMW improperly designated vehicles as demonstrators or loaners so they would be counted as sold when in actuality they were not. Without admitting to or denying the order’s findings, BMW agreed to a settlement to pay $18 million and cease and desist from future violations.On this news, BMWYY ADRs fell $0.51 per ADR, or approximately 2.2%, to close at $23.07 per ADR on September 25, 2020. The same day, BAMXF ADRs fell $2.54, or about 3.5%, to close at $68.91.The complaint, filed on October 27, 2020, alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) BMW kept a “bank” of retail vehicle sales that it used to meet internal monthly sales targets regardless of when the sales actually occurred; (2) BMW artificially manipulated sales figures by having dealers register cars as sold when the cars were still in inventory; (3) as a result, BMW’s key operating metrics were inaccurate and misleading; and (4) as a result, defendants’ statements about BMW’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.For more information on the BMW class action go to: https://bespc.com/cases/BMWZosano Pharma Corporation (NASDAQ: ZSAN) Class Period: February 13, 2017 to September 30, 2020Lead Plaintiff Deadline: December 28, 2020Zosano is a clinical stage pharmaceutical company. Its lead product candidate is Qtrypta (M207), a formulation of zolmitriptan coated onto the Company’s microneedle patch. Its pivotal efficacy trial, called ZOTRIP, began in July 2016. In December 2019, Zosano submitted its New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) seeking regulatory approval for Qtrypta.On September 30, 2020, Zosano disclosed receipt of a discipline review letter (“DRL”) from the FDA regarding its NDA for Qtrypta and stated that approval was not likely. According to the Company’s press release, the FDA “raised questions regarding unexpected high plasma concentrations of zolmitriptan observed in five study subjects from two pharmacokinetic studies and how the data from these subjects affect the overall clinical pharmacology section of the application.” The FDA also “raised questions regarding differences in zolmitriptan exposures observed between subjects receiving different lots of Qtrypta in the company’s clinical trials.”On this news, the Company’s share price fell $0.92, or 57%, to close at $0.70 per share on October 1, 2020.On October 21, 2020, Zosano disclosed receipt of a Complete Response Letter (“CRL”) from the FDA. As a result of the previously identified deficiencies, the FDA recommended that Zosano conduct a repeat bioequivalence study between three of the lots used during development.On this news, the Company’s share price fell $0.17, or 27%, to close at $0.04440 per share on October 21, 2020.The complaint, filed on October 29, 2020, alleges that throughout the Class Period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that the Company’s clinical results reflected differences in zolmitriptan exposures observed between subjects receiving different lots; (2) that pharmocokinetic studies submitted in connection with the Company’s NDA included patients exhibiting unexpected high plasma concentrations of zolmitriptan; (3) that, as a result of the foregoing differences among patient results, the FDA was reasonably likely to require further studies to support regulatory approval of Qtrypta; (4) that, as a result, regulatory approval of Qtrypta was reasonably likely to be delayed; and (5) as a result of the foregoing, defendants’ public statements were materially false and misleading at all relevant times.For more information on the Zosano class action go to: https://bespc.com/cases/ZSANAbout Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.Contact Information: Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Melissa Fortunato, Esq. Marion Passmore, Esq. (212) 355-4648 firstname.lastname@example.org www.bespc.com
The Foam Insulation Market will grow by USD 5.53 bn during 2020-2024